Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects.
The objective of this study was to investigate the therapeutic effects of doxorubicin bound to polysorbate-coated nanoparticles that had previously been shown to significantly enhance survival in the orthotopic rat 101/8 glioblastoma model. Tumor-bearing animals were subjected to chemotherapy using doxorubicin in solution (Dox-sol) or doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles (Dox-np) injected intravenously on Days 2, 5 and 8 post tumor implantation. The antitumor effect was assessed on Days 10, 14 and 18 post tumor implantation. Tumors showed signs of malignancy including invasion of brain tissue, brisk mitotic activity, microvascular proliferation, necrosis and increased proliferation resembling human glioblastoma. Dox-np produced a considerably more pronounced antitumor effect exhibited as a reduced tumor size, lower proliferation, and a decreased necrotic area compared to Dox-sol and to untreated control groups. A drastic effect of Dox-np on vascularization indicated an antiangiogenic mode of action.
Hekmatara
T
T
Institute of Pharmaceutical Technology, J.-W Goethe-University, Frankfurt/Main, Germany.
Bernreuther
C
C
Khalansky
A S
AS
Theisen
A
A
Weissenberger
J
J
Matschke
J
J
Gelperina
S
S
Kreuter
J
J
Glatzel
M
M
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D004317:Doxorubicin / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007150:Immunohistochemistry; D008297:Male; D053758:Nanoparticles; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D011136:Polysorbates / Q000008:administration & dosage; D051381:Rats; D017208:Rats, Wistar
D020533:Angiogenesis Inhibitors; D011136:Polysorbates; D004317:Doxorubicin